SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(UDEN AM)
 

Search: WFRF:(UDEN AM) > Intensive chemother...

Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase - a report from the Swedish CML Group

Turesson, Ingemar (author)
Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine
Axdorph, U (author)
Karolinska Institutet
Vilen, L (author)
show more...
Stenke, L (author)
Karolinska Institutet
Uden, AM (author)
Grimfors, G (author)
Bjorkholm, M (author)
Karolinska Institutet
Carneskog, J (author)
Hansen, J (author)
Linder, O (author)
Ljungman, P (author)
Karolinska Institutet
Lofvenberg, E (author)
Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi
Malm, Claes, 1945- (author)
Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Hematologi,Hematologiska kliniken US
Simonsson, B (author)
Uppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar
Vilen, L (author)
Uden, AM (author)
Bjorkholm, M (author)
show less...
 (creator_code:org_t)
2002-08-29
2002
English.
In: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 118, s. 1048-
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • In attempting to restore the chronic phase (CP) of chronic myelogenous leukaemia (CML), the Swedish CML group utilized an intensive chemotherapy protocol for 83 patients (aged 16-79 years) in accelerated (AP, n = 22) or blastic phase (BC, n = 61). Most patients received a combination of mitoxantrone (12 mg/m(2) /d) and etoposide (100 mg/m(2) /d) together with cytosine arabinoside (1 g/m(2) b.i.d) for 4 d. Overall, 39 patients (47%) achieved a second CP (CP2)/partial remission (PR). Responding patients < 65 years were eligible for ablative chemotherapy followed by an allogeneic (SCT) or a double autologous stem cell transplant (ASCT). Seventeen of 34 responders < 65 years failed to proceed to transplantation as a result of early disease progression (n = 15) or disease-related complications (n = 2). The remaining 17 patients underwent SCT (n = 9; including four unrelated donor SCT) or ASCT (n = 8). Only one of the eight ASCT patients had a second ASCT; the remaining seven failed because of progression (n = 5) or hypoplasia (n = 2). The median duration of CP2/PR was 6 months (range 1-72 months). Five patients achieved a longer CP2/PR than CP1. The 1 year survival was 70% for SCT/ASCT patients (median survival 21 months), 50% for responding patients overall, but only 7% for non-responders (P < 0.001). Three SCT/ASCT patients are long-term survivors (65+, 66+ and 73+ months). In conclusion, approximately half of the patients achieved a CP2/PR after intensive chemotherapy, with a clear survival advantage for responders vs non-responders. Subsequent SCT/ASCT was feasible for half of the responders (< 65 years), and one individual underwent double ASCT. Novel therapeutic options for CML patients in AP/BP are needed.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Keyword

accelerated/blastic phase
CML
stem cell transplantation
MEDICINE

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view